RxDoctor Payments Data

William Postma, MD

Sports Medicine · Washington, DCNPI 1821249897

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.8%), education and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Vericel Corporation at 59.8% of the total. Reporting peaked in 2024 at $11,154 and has fallen 94.8% since, to $579 in 2025.

$17,958in general payments, 2019–2025

Across 37 payments — averaging $485.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vericel Corporation$11K
  • Supreme Orthopedic Systems, LLC$6K
  • Stryker$997
  • Globus Medical$375
  • Johnson & Johnson$84
  • Linvatec Corporation$33
  • plus $70 from 4 others
$3,750in research payments, 2019–2025

Across 1 payment — averaging $3750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vericel Corporation$4K

What the payments were for

  • Speaking & faculty fees$10,37558%
  • Travel & lodging$1141%
  • Food & beverage$2,24713%
  • Education$5,22229%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,958 in reported general payments places this provider in the 80th percentile of 20 sports medicine providers in District of Columbia.

See all sports medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$77,956
Medicare patients
205
Services billed
1,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium44$620

Paid to pharmacies, not to this prescriber.

Other sports medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →